Cyclopharm Ltd (CYC) - Total Liabilities
Based on the latest financial reports, Cyclopharm Ltd (CYC) has total liabilities worth AU$18.99 Million AUD (≈ $13.44 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CYC net asset momentum to track the company's year-over-year net asset growth rate.
Cyclopharm Ltd - Total Liabilities Trend (2005–2025)
This chart illustrates how Cyclopharm Ltd's total liabilities have evolved over time, based on quarterly financial data. See Cyclopharm Ltd (CYC) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Cyclopharm Ltd Competitors by Total Liabilities
The table below lists competitors of Cyclopharm Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bluebird bio Inc
NASDAQ:BLUE
|
USA | $353.82 Million |
|
Focus Lighting and Fixtures Limited
NSE:FOCUS
|
India | Rs656.70 Million |
|
Asia Sejahtera Mina Tbk
JK:AGAR
|
Indonesia | Rp77.18 Billion |
|
Suominen Oyj
HE:SUY1V
|
Finland | €177.19 Million |
|
Circus SE
XETRA:CA1
|
Germany | €16.62 Million |
|
Isbir Holding AS
IS:ISBIR
|
Turkey | TL612.58 Million |
|
Batm Advanced Communications Ltd
TA:BVC
|
Israel | ILA47.67 Million |
|
Greatland Resources Limited
LSE:GGP
|
UK | GBX371.74 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Cyclopharm Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CYC market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cyclopharm Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cyclopharm Ltd (2005–2025)
The table below shows the annual total liabilities of Cyclopharm Ltd from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | AU$18.99 Million ≈ $13.44 Million |
-2.10% |
| 2024-12-31 | AU$19.40 Million ≈ $13.72 Million |
+42.05% |
| 2023-12-31 | AU$13.65 Million ≈ $9.66 Million |
+4.99% |
| 2022-12-31 | AU$13.01 Million ≈ $9.20 Million |
+2.62% |
| 2021-12-31 | AU$12.67 Million ≈ $8.97 Million |
+13.57% |
| 2020-12-31 | AU$11.16 Million ≈ $7.90 Million |
+19.68% |
| 2019-12-31 | AU$9.32 Million ≈ $6.60 Million |
+43.00% |
| 2018-12-31 | AU$6.52 Million ≈ $4.61 Million |
+6.41% |
| 2017-12-31 | AU$6.13 Million ≈ $4.34 Million |
+55.01% |
| 2016-12-31 | AU$3.95 Million ≈ $2.80 Million |
+14.96% |
| 2015-12-31 | AU$3.44 Million ≈ $2.43 Million |
+7.29% |
| 2014-12-31 | AU$3.21 Million ≈ $2.27 Million |
-40.08% |
| 2013-12-31 | AU$5.35 Million ≈ $3.78 Million |
-11.56% |
| 2012-12-31 | AU$6.05 Million ≈ $4.28 Million |
-9.58% |
| 2011-12-31 | AU$6.69 Million ≈ $4.73 Million |
-20.15% |
| 2010-12-31 | AU$8.38 Million ≈ $5.93 Million |
+46.54% |
| 2009-12-31 | AU$5.72 Million ≈ $4.04 Million |
+3.47% |
| 2008-12-31 | AU$5.52 Million ≈ $3.91 Million |
+51.95% |
| 2007-12-31 | AU$3.64 Million ≈ $2.57 Million |
-62.24% |
| 2006-12-31 | AU$9.63 Million ≈ $6.81 Million |
-0.29% |
| 2005-12-31 | AU$9.66 Million ≈ $6.83 Million |
-- |
About Cyclopharm Ltd
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribu… Read more